Consort 2010 statement: extension to cluster randomised trials

Abstract In age-related neurodegenerative disease, like Alzheimer’s and Parkinson’s disease, disease-specific proteins become aggregation-prone and form amyloid-like deposits. Depletion of SERF proteins ameliorates this toxic process in worm- and human cell models for disease. Whether SERF modifies amyloid pathology in mammalian brain, however, has remained unknown. Here, we generated SERF2 brain-specific knockout mice which, unlike full body knockout mice, were viable, and showed no major behavioral and cognitive abnormalities. We combined these knockout mice with the APPPS1 mouse model for human amyloid beta aggregation. Using structure-specific amyloid dyes, previously used to distinguish amyloid…

• UD
  U.S. Department of Health and Human Services
• SG
  Scottish Government
• CR
  Cancer Research UK

  Award: C5529
• NI
  National Institutes of Health
• CS
  Chief Scientist Office, Scottish Government Health and Social Care Directorate
• MR
  Medical Research Council

  Award: MR/J004871/1
• NC
  National Cancer Institute